Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20199503 | 0.96 | CYP1A2 (0.30) | CYP1A2CYP3A4GAAMAPTCYP2C9 | |
| SCHEMBL20199450 | 0.94 | CYP1A2 (0.30) | CYP1A2CYP3A4GAAMAPTCYP2C9 | |
| SCHEMBL20199796 | 0.93 | MAPT (0.31) | CYP1A2CYP3A4GAAMAPTCYP2C9 | |
| SCHEMBL20199580 | 0.89 | MAPT (0.39) | CYP1A2CYP3A4GAAMAPTCYP2C9 | |
| SCHEMBL25121853 | 0.88 | MAPT (0.39) | MAPTNPSR1 | |
| SCHEMBL17245608 | 0.88 | MEN1 (0.31) | — | |
| SCHEMBL25121683 | 0.88 | MAPT (0.40) | CYP1A2CYP3A4GAAMAPTCYP2C9 | |
| SCHEMBL19104484 | 0.87 | MEN1 (0.33) | MAPT | |
| SCHEMBL20199756 | 0.87 | KDM4E (0.36) | MAPT | |
| SCHEMBL20199737 | 0.87 | KDM4E (0.32) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001752-B2 | Double spiro organic compound and organic electronic element comprising same | LG CHEM, LTD. (KR) | 2021-05-11 | — | — | US | disclosed |
| US-20180148640-A1 | DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
| US-20180148640-A1 | DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001752-B2 | Double spiro organic compound and organic electronic element comprising same | DCX, TERT, TELO2 | CYP1A2 1649/4885CYP3A4 1600/4885GAA 1919/4885 |
| US-20180148640-A1 | DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME | DCX, TERT, TELO2 | CYP1A2 1649/4885CYP3A4 1600/4885GAA 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.